Dewpoint Therapeutics develops first-in-class condensate‑modulating small molecules (c‑mods) to target previously intractable biology. Its lead program, DPTX3186, is an orally delivered c‑mod designed to selectively disrupt oncogenic Wnt/β‑catenin signaling and is being advanced into clinical trials. The company also plans to accelerate a c‑mod program targeting MYC. Dewpoint’s platform is AI/ML‑powered and supports a pipeline across oncology, neurodegenerative, cardiopulmonary, and metabolic diseases. It maintains collaborations with Bayer, Novo Nordisk, and Mitsubishi Tanabe Pharma to help translate condensate biology into medicine. The Series D financing extends operational runway into early 2027 and supports clinical proof‑of‑concept goals for DPTX3186 in gastric cancer by the end of 2026. Dewpoint Therapeutics applies the emerging understanding of biomolecular condensates to drug discovery, operating a fully integrated, multi-component biology platform and an AI-driven data science platform. The company advances a pipeline of over 20 discovery and development programs spanning oncology, neuromuscular, cardiopulmonary, and virology indications. Proceeds from its recent financing will fund advancement of multiple programs through IND and further investment in platform and data science capabilities. Dewpoint also plans to expand research infrastructure to support its growing pipeline. The company is led by CEO Ameet Nathwani and has scientific teams in Boston, Dresden, and Berlin. It is headquartered in Boston, MA. Dewpoint Therapeutics applies emerging biomolecular condensate biology to drug discovery through a proprietary, high‑throughput platform that detects and modulates condensate behavior. The platform tests libraries of potential drugs to identify compounds that dissolve, form, stabilize, change composition of, or selectively deliver payloads into condensates. Dewpoint plans to use proceeds from its recent financing to further develop the platform and identify additional condensate‑modulating compounds. The company has announced collaborations with Merck (for an HIV program) and Bayer (for cardiovascular and gynecological programs) and is exploring opportunities in oncology, neurodegeneration, metabolic disease, and immunology. Dewpoint’s team includes researchers and executives who have collectively brought more than ten drugs to market, and its scientific founders include Tony Hyman and Rick Young. The company operates research teams in Boston, Dresden, and Berlin. Dewpoint Therapeutics is building a proprietary platform to drug biomolecular condensates, membrane-less cellular compartments that have been difficult to analyze with traditional drug‑discovery methods. The company leverages recent insights from founders Anthony Hyman and Richard Young and an interdisciplinary mix of soft matter physics, biophysics, computation, and biology to enable new therapeutic approaches. Leadership includes CEO Amir Nashat and Chief Scientific Officer Mark Murcko, and the company has assembled a broad scientific advisory board chaired by MIT’s Phillip Sharp. Dewpoint is industrializing condensate-directed discovery by building teams in Cambridge, MA and Dresden, Germany. Target disease areas called out by the company include cancer, neurodegenerative disorders, immunology, cardiovascular disease, women’s health, and virology. The company launched with a $60 million Series A to advance its platform and progress programs toward therapeutic discovery.

Total raised

$287M

Funding rounds

4

Latest round

Series C

Latest activity

Feb 2022